EuroBiotech: More Articles of Note


> 4SC licensed Kv1.3 inhibitors to Maruho. The deal could net 4SC more than €200 million ($230 million) in milestones if Maruho turns the preclinical compound class into a commercial product. Statement

> One Nucleus named Toby Jones as its chief executive. The Cambridge, U.K.-based life science membership organization is promoting Jones to replace outgoing leader Harriet Fear. Release

> Targovax sold about 320,000 of the 2 million shares it offered. Statement


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> Can-Fite took a step toward enrolling patients in its phase 2 non-alcoholic fatty liver disease trial by completing the investigator meeting. The three-arm, 60-patient clinical trial is assessing the effect of namodenoson on liver triglyceride concentrations. Release

> Paion raised €8 million ($9 million) in a private placement. The German specialty pharma company plans to use the money to prepare for a European phase 3 trial of remimazolam in general anesthesia. Statement

> BrainStorm Cell Therapeutics enlisted Massachusetts General Hospital and California Pacific Medical Center to enroll patients in a phase 3 trial of its amyotrophic lateral sclerosis candidate. Release

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.